PUBLICATION: Original Research
Njomo, D.W., Amuyunzu-Nyamongo, M., Magambo, J.K., Ngure, P.K., & Njenga, S.M.
Lymphatic filariasis (LF), a mosquito-transmitted disease, is ranked as the second largest cause of disability in the world.1 Infection leads to clinical manifestations which include lymphoedema of limbs and genitalia (especially hydroceles) and
elephantiasis. By 2004, about 41 million people worldwide had visible symptoms.2 A further 76 million have hidden infections, most often with microfilariae (mf) in their blood and hidden internal damage to their lymphatic and renal systems.3 About 44 million infected patients have recurrent infections and abnormalities of renal functions.3 The World Health Organization (WHO) recommends that a single dose of DEC or ivermectin, combined with albendazole, be given annually for four to six years to all populations living in endemic areas to eliminate LF.